New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer. In a first-of-its-kind study, the researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer to find evidence for increased and potentially unique genetic testing recommendations. Continue reading
One in six Black men in the United States will be diagnosed with prostate cancer in his lifetime versus one in eight white men. Black men are more likely to be diagnosed at a younger age, with more aggressive disease, and are more than twice as likely to die of prostate cancer. New findings from Prostate Cancer Foundation (PCF)-funded investigators shed light on the genetic underpinnings of this racial disparity and point the way toward more effective screening strategies. Continue reading
Healthy.io, the global leader in transforming the smartphone camera into a medical device, announced today that the U.S. Patent and Trademark Office (USPTO) has awarded the company three patents for the technology behind its Minuteful Wound app. The app enables nurses and healthcare assistants to scan chronic wounds using a standard smartphone camera, with the simple process of shooting an ordinary five-second video. Following this scan, the app runs a set of computer-vision and deep-learning algorithms to analyze the data and translate it into clinical outputs. These include a 3D reconstruction of the wound area, a breakdown of the state of the tissues, and the exact size of the wound. Continue reading
Organ transplantation is a life-saving therapy for millions of patients and one of the greatest successes of modern medicine. However, a limited supply of donor organs, paired with a massive demand for transplants, has fuelled the global organ trafficking industry which exploits poor, underprivileged and persecuted members of society as a source of organs to be purchased by wealthy transplant tourists.
A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography (‘OCT’) technology, which can transform patient’s treatment and care of basal cell carcinomas (BCC). It was concluded that OCT-guided diagnosis, when compared to a standard punch biopsy could reduce the number of consultations and invasive procedures by a massive 66%. Continue reading